#United States #California #Securities Fraud #deramiocel #Capricor Therapeutics

Capricor Therapeutics Faces Legal Challenges

Capricor Therapeutics, Inc., a biotechnology company known for its innovative approach to cell and exosome-based therapies, finds itself in legal hot water following a significant drop in its stock value. The company is facing a class action lawsuit induced by claims of securities fraud, with allegations stemming from potentially misleading statements pertaining to its lead product candidate, Deramiocel, which is aimed at treating Duchenne muscular dystrophy (DMD).

Overview of the Lawsuit

The law firm Bleichmar Fonti & Auld LLP has initiated this class action lawsuit against Capricor and several of its senior executives. The firm emphasizes that these legal actions are a response to the 64% plunge in Capricor's stock value, which dropped from $19.70 to $7.00 per share in late July 2026. Investors who feel they have been misled regarding the efficacy and safety of Deramiocel may consider joining the class action.

The class action complaint posits that Capricor made misleading statements about the clinical data in support of its Biologics License Application (BLA) for Deramiocel. Investors have until September 28, 2026, to respond if they seek to be appointed as lead plaintiffs in the case. The ongoing lawsuit is filed in the U.S. District Court for the Southern District of California under the case name Nkamga v. Capricor Therapeutics, Inc. et al.

Critical Events Leading to the Stock Drop

Capricor’s troubles began after the FDA issued a Complete Response Letter in July 2025, indicating that the company had not provided adequate evidence of the drug's effectiveness, thus delaying its approval for market entry. Compounding this, it is alleged that Capricor made undisclosed changes to the analysis plan for clinical trial data, which were not agreed upon by the FDA prior to submitting the revised BLA.

The turning point came on July 27, 2026, when the FDA released briefing documents for an advisory committee meeting, raising red flags regarding the statistical analysis methods employed by Capricor. This included post-hoc adjustments to critical endpoints, which had not been disclosed to investors, leading to a dramatic decline in stock value.

Following the FDA's advisory committee meeting and a non-binding vote against the drug's efficacy, the stock suffered further losses, plummeting from $6.57 to $4.19 within a two-day period. The financial repercussions of these developments have sparked outrage among investors and triggered the lawsuit.

What's Next for Capricor and Investors?

Investors who have been affected by Capricor's stock plummet are encouraged to explore their legal options. The law firm Bleichmar Fonti & Auld LLP operates on a contingency basis, meaning that investors do not bear any upfront costs while pursuing the lawsuit. Successful litigation could lead to the recovery of significant financial losses for those who invested in Capricor during this period.

As this case unfolds, it emphasizes the critical role of transparency and integrity within the biotechnology sector—especially in regards to clinical data used in drug approval processes. Stakeholders are closely watching the developments as Capricor navigates its legal challenges. Should the allegations hold water, this could lead to significant regulatory and operational changes within the firm as it seeks to reassure investors and restore its credibility in the market.

For more information about the ongoing class action and how to participate, affected investors are advised to visit the law firm's dedicated webpage.